依托泊苷+顺铂方案与依托泊苷+卡铂方案治疗广泛期小细胞肺癌的近期疗效及毒副反应  

Comparison of short-term efficacy and toxicities between first-line toposide+cisplatin and etoposide+cisplatin chemotherapy regimens in the treatment of extensive-stage small-cell lung cancer

作　　者：骆启春 柯维芳 周璐 LUO Qichun;KE Weifang;ZHOU Lu(Department of Oncology,Dongxin Fifth Hospital of Shangrao,Shangrao,Jiangxi,334000,China)

机构地区：[1]上饶市东信第五医院肿瘤科,江西上饶334100

出　　处：《当代医学》2024年第36期72-75,共4页Contemporary Medicine

摘　　要：目的探究EP[依托泊苷(etoposide,VP-16)+顺铂(cisplatin,DDP)]方案与EC[VP-16+卡铂(carboplatin,CBP)]方案治疗广泛期小细胞肺癌(extensive-stage small-cell lung cancer,ED-SCLC)的近期疗效及毒性反应。方法选取2019年6月至2021年12月上饶市东信第五医院收治的80例ED-SCLC患者作为研究对象,按照随机数字表法分为EP组与EC组,每组40例。EP组采用VP-16+DDP方案化疗,EC组采用VP-16+CBP方案化疗,比较两组临床疗效、毒副反应及血清标志物。结果两组客观有效率、疾病控制率比较差异无统计学意义。治疗后,两组细胞核增殖抗原(Ki-67)、血管内皮生长因子(vascular endothelial growth factor,VEGF)水平均低于治疗前,且EP组低于EC组,差异有统计学意义(P<0.05)。EP组中细粒细胞及血小板减少发生率均低于EC组,差异有统计学意义(P<0.05),其余毒副反应发生率比较差异无统计学意义。结论EP方案与EC方案治疗ED-SCLC患者临床疗效相当,但EP方案治疗毒性反应较少,能降低Ki-67及VEGF水平。Objective To investigate short-term efficacy and toxicities of EP(etoposide,[VP-16]+cisplatin[DDP])regimen and EC(VP-16+carboplatin[CBP])regimen in the treatment of extensive-stage small-cell lung cancer(ED-SCLC).Methods 80 patients with ED-SCLC admitted to Dongxin Fifth Hospital of Shangrao from June 2019 to December 2021 were selected as the research subjects,and they were divided into the EP group and the EC group according to the random number table method,with 40 cases in each group.The EP group underwent VP-16+DDP chemotherapy,while the EC group underwent VP-16+CBP chemotherapy,the clinical efficacy,toxicities and serum markers were compared between the two groups.Results There were no significant difference in objective response rate or disease control rate between the two groups.After treatment,the levels of proliferating cell nuclear-associated antigen Ki-67 and vascular endothelial growth factor(VEGF)of the two groups were lower than those before treatment,and the EP group was lower than the EC group,the differences were statistically significant(P<0.05).The incidence of granulocyte reductionand platelet in the EP group were lower than those in the EC group,the differences were statistically significant(P<0.05),there was no significant difference in the incidence of the other toxicities.Conclusion Clinical efficacy of EP regimen and EC regimen in the treatment of patients with ED-SCLC are comparable,however,the EP regimen had fewer toxic reactions to treatment and was more able to reduce Ki-67 and VEGF levels.

关 键 词：广泛期小细胞癌 依托泊苷 顺铂 卡铂 毒副反应 血清标志物 

分 类 号：R73[医药卫生—肿瘤]